Quiz: Multiple Myeloma Patients With AL Amyloidosis

Article

Challenge yourself with our latest quiz covering management of AL amyloidosis in the treatment of patients with multiple myeloma.

Question 1

Answer

A.Amyloid light-chain (AL) amyloidosis

Multiple myeloma and AL amyloidosis are both caused by the expansion of monoclonal plasma cells and each involve dysproteinemia. Each disease state can occur independently, but in rare instances AL amyloidosis occursin patients diagnosed with multiple myeloma.

Question 2

Answer

D.All of the above

Multiple myeloma-associated AL amyloidosis can affect any organ system, including myocardia, renal, bone, dermal and subcutaneous tissues.

Question 3

Answer

C.Poor survival

A recent review of 32 published cases suggested a higher prevalence of concurrent cutaneous AL amyloidosis and multiple myeloma in women (66% of cases). Nineteen of the 32 patients were white. Most (64%) of the patients died within 6 months of diagnosis.

Question 4

Answer

B.56%

Most (56%) of the 32 published cases of concurrent AL amyloidosis and multiple myeloma reviewed presented as hemorrhagic bullous lesions. Another 25% presented as purpura/ecchymosis.

Question 5

Answer

C.Cardiac failure

AL amyloidosis is commonly classified to reflect whether cardiac, renal, gastrointestinal, pulmonary, or other tissues are primarily affected by amyloid depositions. Symptoms vary depending on involved organ systems but the most common cause of death for these patients is cardiac failure.

Recent Videos
“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.
Barry Paul, MD, listed cilta-cel, anito-cel, and arlo-cel as 3 of the CAR T-cell therapies with the most promising efficacy in patients with multiple myeloma.
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
Long-term toxicities like infections and secondary primary malignancies remain a concern when sequencing novel agents for those with multiple myeloma.
Management of adverse effects and access to cellular therapies among community oncologists represented key points of discussion in multiple myeloma.
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
Related Content